Our vision is to be the global leaders in prescription cannabinoid medicines, through the rapid cost-effective development of pharmaceutical products which address clear unmet needs.
GW is developing a portfolio of cannabinoid medicines, including Sativex for the treatment of MS spasticity and cancer pain, and Epidiolex for the treatment of childhood epilepsy.

Type
Public
HQ
Histon, GB
Founded
1998
Size (employees)
496 (est)
GW Pharmaceuticals was founded in 1998 and is headquartered in Histon, GB
Report incorrect company information

GW Pharmaceuticals Office Locations

GW Pharmaceuticals has offices in Histon, London and Carlsbad
Histon, GB (HQ)
Vision Park
London, GB
1 Cavendish Pl
Carlsbad, US
210 5800 Armada Dr
Show all (3)
Report incorrect company information

GW Pharmaceuticals Financials and Metrics

GW Pharmaceuticals Financials

GW Pharmaceuticals's revenue was reported to be £8.24 m in FY, 2017
GBP

Revenue (FY, 2017)

8.2 m

Gross profit (FY, 2017)

4.7 m

Gross profit margin (FY, 2017), %

57%

Net income (FY, 2017)

(131.7 m)

EBITDA (FY, 2017)

(147.8 m)

EBIT (FY, 2017)

(153.3 m)

Market capitalization (31-Oct-2017)

2.7 b

Closing share price (31-Oct-2017)

106.2

Cash (30-Sep-2017)

241.2 m
GW Pharmaceuticals's current market capitalization is $2.7 b.
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

5.7 m11.8 m24.1 m30.7 m29.6 m33.1 m27.3 m30 m28.5 m10.3 m8.2 m

Revenue growth, %

10%(5%)(64%)

Cost of goods sold

254 k249 k433 k752 k1.3 m839 k1.3 m2.1 m2.6 m2.7 m3.5 m

Gross profit

5.4 m11.5 m23.7 m29.9 m28.3 m32.3 m26 m28 m25.9 m7.6 m4.7 m
GBPY, 2017

Revenue/Employee

16.6 k

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information

GW Pharmaceuticals News and Updates

Corix Biosciences, Inc. (OTCQB: CXBS) - GW Pharmaceuticals (NASDAQ: GWPH) Should Acquire This

This article is published in collaboration with Scutify, where you can find real-time markets a
Report incorrect company information